Covid19 PneumoniaCOVISQARNCT04881214
COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program
A study testing Pulmonary rehabilitation in people with Covid19 Pneumonia and Chronic Thromboembolic Pulmonary Hypertension, run by University Hospital, Geneva at 1 site in Switzerland.
Trial summary
The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity resulting in severe hypoxemia during the active phase of the disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension, Myopathy
- What is being tested?
- Pulmonary rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jul 2020to 30 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Patients will be eligible for inclusion if they fulfil all the following criteria:
- Patients aged ≥ 18 years.
- Confirmed diagnosis of SARS-Cov-2 infection by nasal swab, other viral sample (i.e. sputum, bronchoalveolar lavage) or Chest imaging suggestive of SARS-CoV-2 pneumonia (Chest X-ray or CT-scan).
- Requirement for oxygen supplementation.
- Persistent respiratory symptoms (i.e. dyspnoea, cough) or asthenia.
- Abnormal 6MWT at 3 months (distance < 90% predicted or desaturation ≥ 3% or Borg >5) and/or abnormal lung function as described by the international recommendations
Patients will be excluded if they:
- Already had existing severe and symptomatic pulmonary condition before COVID-19 pneumonia
- Are unable to execute the different tests and surveys because of cognitive or physical limitations.
- Are already included in a structured rehabilitation program
- Have comorbidities with a life expectancy of less than 12 months.
- Any relevant acute medical disorder/acute disease state judged by the investigators as likely to represent a risk for the patient to fulfil a rehabilitation program or requiring urgent investigations.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)
The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity resulting in severe hypoxemia during the active phase of the disease. Additional skeletal muscle impairment related to systemic inflammation may also explain persisting symptoms in the follow-up phase. The first aim of the present project is to explore these different processes by evaluating the impact of the COVID-19 pneumonia on exercise capacity, pulmonary function and perfusion by a physiological and radiologic study. An ambulatory pulmonary rehabilitation will also be studied to assess its impact on the physiological parameter mentioned and the health-related quality of life questionnaire as a potential long-term treatment. The investigators propose a single center randomized controlled study at the University Hospitals of Geneva. 60 adult patients having suffered a hypoxemic COVID-19 pneumonia with persistent symptoms at 3-months after hospital discharge will be included. A functional and physiological study will be performed, including a six-minute walk test, pulmonary function testing, diffusing capacity for carbon monoxide, maximal inspiratory pressure and sniff nasal inspiratory pressure. Those with at least one abnormal value will be invited to fill the Saint Georges Respiratory Questionnaire, the Short Form 36 and the Hospital Anxiety and Depression Scale and will undergo a chest dual energy computed tomography (DECT), a cardiopulmonary exercise testing with non-invasive cardiac output and stroke volume evaluation and an evaluation of the pulmonary shunt by hyperoxia (100% oxygen breathing) at rest and during light effort. Then patients will be randomized on a 1:1 basis for pulmonary rehabilitation program or usual care. All work-up except DECT will be repeated at 6 and 12 months after hospital discharge. The investigators hypothesize that our study will allow a better understanding of pathophysiological mechanisms involved in COVID-19. This will potentially determine therapeutic target for patients with persisting symptoms and functional decay after COVID-19. The investigators also expect to see an improvement of exercise capacity and physiological parameters in the pulmonary rehabilitation group, as compared to the control group, suggesting pulmonary rehabilitation as a possible long-term treatment of this condition.
Read the detailed description
COVID-19 is an emerging pandemic disease caused by a novel coronavirus (SARS-CoV-2) since December 2019. This condition may be associated with a severe pneumonia and an acute respiratory distress syndrome (ARDS) resulting in a high mortality and morbidity.A standardized follow up of COVID-19 patients after discharge from Geneva University Hospitals (Covicare) was implemented since March 29th 2020 by the divisions of infectious disease and respiratory medicine, in association with the primary care medicine department. A follow-up is ensured until one month after discharge. All patients are registered in a database (REDCapTM,Tennessee, USA).
The pathophysiological mechanisms of ARDS in COVID-19 and its long-term consequences on respiratory and cardiovascular systems remain unclear. Several histopathological studies have demonstrated occurrence of interstitial lung disease. Furthermore, there are some reports of associated endothelitis, thrombosis in the microcirculation5 and a high prevalence of venous thrombo-embolic events in ICU admitted patients, with pulmonary embolism accounting for 85% of those events.Both these changes contribute to increase heterogeneity of ventilation - perfusion ratio (VA/Q), thereby widening the alveolar - arterial oxygen gradient, and thus causing serious hypoxaemia, with remarkable fall of arterial oxygen saturation (SaO2). Finally, the interstitial pneumopathy may cause a persisting reduction of lung diffusing capacity for carbon monoxide (DLCO), further decreasing SaO2 even after recovery from COVID-19 pneumonia.
Chest Dual-Energy Computed Tomography (DECT) enables a combined functional and morphological analysis of the lung in a single and simple acquisition. Because of the attenuation properties of iodine at two different photon energies (80 and 140kV), DECT is able to reveal pulmonary blood volume distribution and generate color-coded pulmonary iodine volume maps, corresponding to the pulmonary perfusion. These pulmonary perfusion maps allow a qualitative analysis of the perfusion.Furthermore, the iodine concentration of the lung confers an objective and quantitative regional analysis of the perfusion. In comparison with a conventional CT, no additional intravenous iodine contrast medium injection or radiation doses are needed; a functional image processing is simply added. We recently demonstrated how DECT may help to define lung perfusion changes after therapeutic measures in patients with chronic obstructive pulmonary disease. Moreover, DECT offers an excellent correlation with perfusion scintigraphy (V/Q scan). DECT also offers a superior anatomic and functional comprehension by simultaneously recording the vascular anatomy, parenchymal morphology, and functional perfusion. Consequently, DECT may provide important information both on persisting parenchymal and perfusion alteration after COVID-19.
In addition to the pulmonary component, the systemic inflammation state due to the concurring "cytokine storm syndrome" may have an important role in the development of neuromuscular alterations, independently of direct consequences of hospitalization in intensive care unit. Neuromuscular alterations concur with lung function impairment in compromising the functional state of the patient. As a consequence, we ought to expect a reduction of physical exercise capacity, which is normally determined by a VO2max measurement during cardiopulmonary exercise test (CPET) and by means of the six-minute walk test (6MWT).
Moreover, it is well described that ARDS is associated with a significant long-term morbidity. At one year, 80% of ARDS survivors have a reduced diffusing capacity and 20% suffer from an airflow obstruction. 35% of patients have an exercise limitation based on the 6MWT at two years. Moreover, impairment in lung function, musculoskeletal dysfunction and functional limitation are linked to health-related quality of life (HRQL) decrement.
Studies from a cohort of patients who suffered from ARDS due to SARS-CoV-1 in 2002 showed a positive correlation between lung function and the HRQL physical functioning domain. Distance performed during 6MWT correlated also with almost all Short Form Health Survey-36 (SF-36) domains. Furthermore, mood disorders are commonly described in ARDS survivors, with studies reporting up to 50% of depression at one year in this population. Depression and anxiety are themselves associated with lower HRQL scores.
Pulmonary rehabilitation has been shown to improve HRQL, maximal exercise capacity and 6MWD in chronic pulmonary disease. It was also shown that 2 months of ambulatory pulmonary rehabilitation improved pulmonary function and the St. George's Respiratory Questionnaire (SGRQ) at 3 and 6 months post-discharge following recovery from ARDS due to severe influenza A (H1N1 in 2009) pneumonitis.
The purpose of this study is 1/ to explore the long-term impact of COVID-19 on physiological respiratory parameters, functional capacity, HRQL and mood disturbances ; 2/ to assess the benefit of a pulmonary rehabilitation program on these outcomes through a randomized-control study, and 3/ to determine the contribution of DECT to the understanding of the pathophysiological alterations in patients with functional sequelae of COVID-19 infection.
- Conditions
- Covid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension, Myopathy, Restrictive Lung Disease
- Being tested
- Pulmonary rehabilitation
- Keywords
- COVID-19, cardiopulmonary rehabilitation, spirometry, thromboembolic disease, non-invasive cardiac output
- Medical subject headings
- Muscular Diseases, COVID-19, Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pulmonary rehabilitationOther
pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Patients in this arm will receive standard of care |
| Pulmonary Rehabilitation | Experimental | Patients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included. Receives: Other: Pulmonary rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of ambulatory pulmonary rehabilitation in health related quality of life
St George's Respiratory questionnaire change (units). Scores range from 0 to 100, with higher scores indicating more limitations
Measured: 12 months
Secondary outcomes (18)
Long-term consequences of COVID-19 pneumonia on VEMS
Change in VEMS (L, % predicted)
Measured: 12 months
Long-term consequences of COVID-19 pneumonia on Vital Capacity
Change in Vital Capacity (L, % predicted)
Measured: 12 months
Long-term consequences of COVID-19 pneumonia on Total Lung Capacity
Change in Total Lung Capacity (L, % predicted)
Measured: 12 months
Long-term consequences of COVID-19 pneumonia on diffusion capacity of CO
Change in diffusion capacity of CO (ml/min/kPa, % predicted)
Measured: 12 months
long-term consequences of COVID-19 pneumonia on Vital Capacity (VC)
absolute value (liters) measured at inclusion and at the end of the study period with spirometry
Measured: 12 months
long-term consequences of COVID-19 pneumonia on total lung capacity (TLC)
absolute value (liters) measured at inclusion and at the end of the study period with plethysmography
Measured: 12 months
long-term consequences of COVID-19 pneumonia on diffusing capacity for carbon monoxide (DLCO)
absolute value (ml/min/kPa) measured at inclusion and at the end of the study period with plethysmography
Measured: 12 months
Incidence of interstitial lung disease and/or images suggestive of abnormalities in the pulmonary circulation.
Evaluated with a chest dual energy Computed Tomography: presence of honeycombing, bronchiectasis or acute or chronic thromboembolism.
Measured: 3 months
Effect of COVID-19 pneumonia on The Short Form 36 (SF-36) questionnaire score
measured at inclusion and at the end of the study. Score from 0 (poor health) to 100 (perfect health)
Measured: 12 months
Effect of COVID-19 pneumonia on Hospital Anxiety and Depression Scale (HADS) score
measured at inclusion and at the end of the study. . Each of them is coded From 0 to 3, with a score varying from 0 to 21
Measured: 12 months
Effect of pulmonary rehabilitation in VO2 max during cardiopulmonary exercise testing (CPET)
Change in VO2 max (ml/min/kg)
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in power during cardiopulmonary exercise testing (CPET)
Change in power max (Watts)
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in ventilation during cardiopulmonary exercise testing (CPET)
Change in ventilation (L/min)
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in Tidal Volume during cardiopulmonary exercise testing (CPET)
Change in Tidal Volume (L)
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in 6 minutes walk test distance
Change in meters
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in 6 minutes walk test dyspnea
Change in self reported Borg dyspnea
Measured: 3,6 and 12 months
Effect of pulmonary rehabilitation in cardiac output during CPET
ANOVA comparison of cardiac output with 2 non-invasive measurement of cardiac output
Measured: 3,6 and 12 months
Evaluation of COVID-19 impact in pulmonary shunt effect
Change in pulmonary shunt (delta kPa)
Measured: 2,6 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2021
- Study start1 Jul 2020
- Primary completion30 Jun 2023 (estimated)
- Study completion30 Jun 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Covid19 PneumoniaStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Collaborators
- Ligue Pulmonaire Genevoise
- Responsible party
- Principal investigator, Frédéric Lador, MD-PhD, University Hospital, Geneva
- Investigators
- Lador Frédéric, MD-PHD, Principal investigator, University Hospital, Geneva
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04881214
- Sponsor's protocol ID
- 2020-001457
- Acronym
- COVISQAR
- Status last verified
- Sep 2022
- First submitted
- 3 Jul 2020
- Last updated
- 23 Sep 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Finegan O, Fonseca S, Guyomarc'h P, Morcillo Mendez MD, Rodriguez Gonzalez J, Tidball-Binz M, Winter KA; ICRC Advisory Group on the Management of COVID-19 Related Fatalities. International Committee of the Red Cross (ICRC): General guidance for the management of the dead related to COVID-19. Forensic Sci Int Synerg. 2020 Mar 31;2:129-137. doi: 10.1016/j.fsisyn.2020.03.007. eCollection 2020.
PubMed 32412013Correction to Lancet Respir Med 2020; 8: 420-22. Lancet Respir Med. 2020 Apr;8(4):e26. doi: 10.1016/S2213-2600(20)30085-0. Epub 2020 Feb 25. No abstract available.
PubMed 32109426Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
PubMed 32114094Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. No abstract available.
PubMed 32325026Guerreiro I, Bringard A, Nehme M, Guessous I, Benzakour L, Juillet De Saint Lager-Lucas A, Taboni A, Lador F. Exercise ventilatory response after COVID-19: comparison between ambulatory and hospitalized patients. Am J Physiol Lung Cell Mol Physiol. 2023 Dec 1;325(6):L756-L764. doi: 10.1152/ajplung.00142.2023. Epub 2023 Oct 24.
PubMed 37874657
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)
- ClinicalTrials.gov ID
- NCT04881214
- Acronym / sponsor ID
- COVISQAR / 2020-001457
- Conditions
- Covid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension, Myopathy, Restrictive Lung Disease
- Keywords
- COVID-19, cardiopulmonary rehabilitation, spirometry, thromboembolic disease, non-invasive cardiac output
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Collaborators
- Ligue Pulmonaire Genevoise
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- 30 Jun 2023 (estimated)
- Study completion
- 30 Jun 2023 (estimated)
- First posted
- 11 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity resulting in severe hypoxemia during the active phase of the disease. Additional skeletal muscle impairment related to systemic inflammation may also explain persisting symptoms in the follow-up phase. The first aim of the present project is to explore these different processes by evaluating the impact of the COVID-19 pneumonia on exercise capacity, pulmonary function and perfusion by a physiological and radiologic study. An ambulatory pulmonary rehabilitation will also be studied to assess its impact on the physiological parameter mentioned and the health-related quality of life questionnaire as a potential long-term treatment. The investigators propose a single center randomized controlled study at the University Hospitals of Geneva. 60 adult patients having suffered a hypoxemic COVID-19 pneumonia with persistent symptoms at 3-months after hospital discharge will be included. A functional and physiological study will be performed, including a six-minute walk test, pulmonary function testing, diffusing capacity for carbon monoxide, maximal inspiratory pressure and sniff nasal inspiratory pressure. Those with at least one abnormal value will be invited to fill the Saint Georges Respiratory Questionnaire, the Short Form 36 and the Hospital Anxiety and Depression Scale and will undergo a chest dual energy computed tomography (DECT), a cardiopulmonary exercise testing with non-invasive cardiac output and stroke volume evaluation and an evaluation of the pulmonary shunt by hyperoxia (100% oxygen breathing) at rest and during light effort. Then patients will be randomized on a 1:1 basis for pulmonary rehabilitation program or usual care. All work-up except DECT will be repeated at 6 and 12 months after hospital discharge. The investigators hypothesize that our study will allow a better understanding of pathophysiological mechanisms involved in COVID-19. This will potentially determine therapeutic target for patients with persisting symptoms and functional decay after COVID-19. The investigators also expect to see an improvement of exercise capacity and physiological parameters in the pulmonary rehabilitation group, as compared to the control group, suggesting pulmonary rehabilitation as a possible long-term treatment of this condition.
Detailed description
COVID-19 is an emerging pandemic disease caused by a novel coronavirus (SARS-CoV-2) since December 2019. This condition may be associated with a severe pneumonia and an acute respiratory distress syndrome (ARDS) resulting in a high mortality and morbidity.A standardized follow up of COVID-19 patients after discharge from Geneva University Hospitals (Covicare) was implemented since March 29th 2020 by the divisions of infectious disease and respiratory medicine, in association with the primary care medicine department. A follow-up is ensured until one month after discharge. All patients are registered in a database (REDCapTM,Tennessee, USA).
The pathophysiological mechanisms of ARDS in COVID-19 and its long-term consequences on respiratory and cardiovascular systems remain unclear. Several histopathological studies have demonstrated occurrence of interstitial lung disease. Furthermore, there are some reports of associated endothelitis, thrombosis in the microcirculation5 and a high prevalence of venous thrombo-embolic events in ICU admitted patients, with pulmonary embolism accounting for 85% of those events.Both these changes contribute to increase heterogeneity of ventilation - perfusion ratio (VA/Q), thereby widening the alveolar - arterial oxygen gradient, and thus causing serious hypoxaemia, with remarkable fall of arterial oxygen saturation (SaO2). Finally, the interstitial pneumopathy may cause a persisting reduction of lung diffusing capacity for carbon monoxide (DLCO), further decreasing SaO2 even after recovery from COVID-19 pneumonia.
Chest Dual-Energy Computed Tomography (DECT) enables a combined functional and morphological analysis of the lung in a single and simple acquisition. Because of the attenuation properties of iodine at two different photon energies (80 and 140kV), DECT is able to reveal pulmonary blood volume distribution and generate color-coded pulmonary iodine volume maps, corresponding to the pulmonary perfusion. These pulmonary perfusion maps allow a qualitative analysis of the perfusion.Furthermore, the iodine concentration of the lung confers an objective and quantitative regional analysis of the perfusion. In comparison with a conventional CT, no additional intravenous iodine contrast medium injection or radiation doses are needed; a functional image processing is simply added. We recently demonstrated how DECT may help to define lung perfusion changes after therapeutic measures in patients with chronic obstructive pulmonary disease. Moreover, DECT offers an excellent correlation with perfusion scintigraphy (V/Q scan). DECT also offers a superior anatomic and functional comprehension by simultaneously recording the vascular anatomy, parenchymal morphology, and functional perfusion. Consequently, DECT may provide important information both on persisting parenchymal and perfusion alteration after COVID-19.
In addition to the pulmonary component, the systemic inflammation state due to the concurring "cytokine storm syndrome" may have an important role in the development of neuromuscular alterations, independently of direct consequences of hospitalization in intensive care unit. Neuromuscular alterations concur with lung function impairment in compromising the functional state of the patient. As a consequence, we ought to expect a reduction of physical exercise capacity, which is normally determined by a VO2max measurement during cardiopulmonary exercise test (CPET) and by means of the six-minute walk test (6MWT).
Moreover, it is well described that ARDS is associated with a significant long-term morbidity. At one year, 80% of ARDS survivors have a reduced diffusing capacity and 20% suffer from an airflow obstruction. 35% of patients have an exercise limitation based on the 6MWT at two years. Moreover, impairment in lung function, musculoskeletal dysfunction and functional limitation are linked to health-related quality of life (HRQL) decrement.
Studies from a cohort of patients who suffered from ARDS due to SARS-CoV-1 in 2002 showed a positive correlation between lung function and the HRQL physical functioning domain. Distance performed during 6MWT correlated also with almost all Short Form Health Survey-36 (SF-36) domains. Furthermore, mood disorders are commonly described in ARDS survivors, with studies reporting up to 50% of depression at one year in this population. Depression and anxiety are themselves associated with lower HRQL scores.
Pulmonary rehabilitation has been shown to improve HRQL, maximal exercise capacity and 6MWD in chronic pulmonary disease. It was also shown that 2 months of ambulatory pulmonary rehabilitation improved pulmonary function and the St. George's Respiratory Questionnaire (SGRQ) at 3 and 6 months post-discharge following recovery from ARDS due to severe influenza A (H1N1 in 2009) pneumonitis.
The purpose of this study is 1/ to explore the long-term impact of COVID-19 on physiological respiratory parameters, functional capacity, HRQL and mood disturbances ; 2/ to assess the benefit of a pulmonary rehabilitation program on these outcomes through a randomized-control study, and 3/ to determine the contribution of DECT to the understanding of the pathophysiological alterations in patients with functional sequelae of COVID-19 infection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Patients in this arm will receive standard of care |
| Pulmonary Rehabilitation | Experimental | Other: Pulmonary rehabilitationPatients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pulmonary rehabilitationpulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months | Other | Pulmonary Rehabilitation |
Primary outcome
Effect of ambulatory pulmonary rehabilitation in health related quality of life
Time frame: 12 months
St George's Respiratory questionnaire change (units). Scores range from 0 to 100, with higher scores indicating more limitations
18 secondary outcomes
Long-term consequences of COVID-19 pneumonia on VEMS
Time frame: 12 months
Long-term consequences of COVID-19 pneumonia on Vital Capacity
Time frame: 12 months
Long-term consequences of COVID-19 pneumonia on Total Lung Capacity
Time frame: 12 months
Long-term consequences of COVID-19 pneumonia on diffusion capacity of CO
Time frame: 12 months
long-term consequences of COVID-19 pneumonia on Vital Capacity (VC)
Time frame: 12 months
long-term consequences of COVID-19 pneumonia on total lung capacity (TLC)
Time frame: 12 months
long-term consequences of COVID-19 pneumonia on diffusing capacity for carbon monoxide (DLCO)
Time frame: 12 months
Incidence of interstitial lung disease and/or images suggestive of abnormalities in the pulmonary circulation.
Time frame: 3 months
Effect of COVID-19 pneumonia on The Short Form 36 (SF-36) questionnaire score
Time frame: 12 months
Effect of COVID-19 pneumonia on Hospital Anxiety and Depression Scale (HADS) score
Time frame: 12 months
Effect of pulmonary rehabilitation in VO2 max during cardiopulmonary exercise testing (CPET)
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in power during cardiopulmonary exercise testing (CPET)
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in ventilation during cardiopulmonary exercise testing (CPET)
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in Tidal Volume during cardiopulmonary exercise testing (CPET)
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in 6 minutes walk test distance
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in 6 minutes walk test dyspnea
Time frame: 3,6 and 12 months
Effect of pulmonary rehabilitation in cardiac output during CPET
Time frame: 3,6 and 12 months
Evaluation of COVID-19 impact in pulmonary shunt effect
Time frame: 2,6 and 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2022.
- Background: PubMed 32412013Finegan O, Fonseca S, Guyomarc'h P, Morcillo Mendez MD, Rodriguez Gonzalez J, Tidball-Binz M, Winter KA; ICRC Advisory Group on the Management of COVID-19 Related Fatalities. International Committee of the Red Cross (ICRC): General guidance for the management of the dead related to COVID-19. Forensic Sci Int Synerg. 2020 Mar 31;2:129-137. doi: 10.1016/j.fsisyn.2020.03.007. eCollection 2020.
- Background: PubMed 32109426Correction to Lancet Respir Med 2020; 8: 420-22. Lancet Respir Med. 2020 Apr;8(4):e26. doi: 10.1016/S2213-2600(20)30085-0. Epub 2020 Feb 25. No abstract available.
- Background: PubMed 32114094Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
- Background: PubMed 32325026Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. No abstract available.
- Derived from this study: PubMed 37874657Guerreiro I, Bringard A, Nehme M, Guessous I, Benzakour L, Juillet De Saint Lager-Lucas A, Taboni A, Lador F. Exercise ventilatory response after COVID-19: comparison between ambulatory and hospitalized patients. Am J Physiol Lung Cell Mol Physiol. 2023 Dec 1;325(6):L756-L764. doi: 10.1152/ajplung.00142.2023. Epub 2023 Oct 24.
- Individual participant dataSharing planned: No
Related trials for Covid19 Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lador Frédéric, MD-PHD principal investigator
University Hospital, Geneva
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pulmonary rehabilitation in people with Covid19 Pneumonia and Chronic Thromboembolic Pulmonary Hypertension, run by University Hospital, Geneva at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of ambulatory pulmonary rehabilitation in health related quality of life (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04881214, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2022.